Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
novel oral poliovirus vaccine (modified)
- Development stage
- Preclinical
- Lead developer
- Codagenix
- Modality
- Live Attenuated Vaccines → Live Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Oral
01
Overview
Novel oral poliovirus vaccine (modified) is a live-attenuated vaccine candidate being developed by Codagenix for the prevention of poliomyelitis. The vaccine is engineered using Codagenix's proprietary codon deoptimization technology, which involves recoding the viral genome with numerous synonymous mutations to reduce the efficiency of viral protein synthesis. This process results in a virus that is antigenically identical to the wild-type poliovirus but possesses significantly reduced replication fitness and a lower risk of reverting to a neurovirulent state compared to traditional oral poliovirus vaccines (OPV). By maintaining the ability to induce robust mucosal immunity while enhancing safety, this modified nOPV aims to support global efforts in polio eradication. The program is currently in the preclinical stage of development.
- Other names
- modified nOPVmodified novel oral poliovirus vaccine
Beyond the preview
Go deeper on novel oral poliovirus vaccine (modified).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on novel oral poliovirus vaccine (modified).